33524 Federal Register / Vol. 61, No. 125 / Thursday, June 27, 1996 / Notices

cooperative agreement and which are

measurable and time-phased. Extent to

which applicant presents a detailed

plan for initiating and conducting the

project which clearly and appropriately

addresses all ‘‘Recipient Activities.’’

Extent to which the plan clearly

describes applicant’s technical

approach/methods for conducting the

proposed studies. Extent to which

applicant describes specific study

protocols or plans for the development

of study protocols that are appropriate

for achieving project objectives. Extent

to which applicant describes adequate

collaboration with CDC during various

phases of the project. Extent to which

applicant provides a detailed plan for

evaluating study results and for

evaluating progress towards achieving

project objectives. (35 points)

D. Budget

Extent to which the proposed budget

is reasonable, clearly justifiable, and

consistent with the intended use of

cooperative agreement funds. (Not

Scored)

Executive Order 12372 Review

This program is not subject to

Executive Order 12372.

Public Health System Reporting

Requirements

This program is subject to the Public

Health System Reporting Requirements.

Under these requirements, all

community-based nongovernmental

applicants must prepare and submit the

items identified below to the head of the

appropriate State and/or local health

agency(s) in the program area(s) that

may be impacted by the proposed

project no later than the receipt date of

the Federal application. The appropriate

State and/or local health agency is

determined by the applicant. The

following information must be

provided:

a. A copy of the face page of the

application (SF 424);

b. A summary of the project that

should be titled ‘‘Public Health System

Impact Statement’’ (PHSIS), not exceed

one page, and include the following:

(1) A description of the population to

be served;

(2) A summary of the services to be

provided;

(3) A description of the coordination

plans with the appropriate State and/or

local health agencies.

If the State and/or local health official

should desire a copy of the entire

application, it may be obtained from the

State Single Point of Contact (SPOC) or

directly from the applicant.

Catalog of Federal Domestic Assistance

Number

The Catalog of Federal Domestic

Assistance Number is 93.283.

Other Requirements

Animal Subjects

If the proposed project involves

research on animal subjects, the

applicant must comply with the ‘‘PHS

Policy on Humane Care and Use of

Laboratory Animals by Awardee

Institutions.’’ An applicant organization

proposing to use vertebrate animals in

PHS-supported activities must file an

Animal Welfare Assurance with the

Office for Protection from Research

Risks at the National Institutes of

Health.

Application Submission and Deadline

The original and two copies of the

application PHS Form 5161–1 (Revised

7/92, OMB Number 0937–0189) must be

submitted to Sharron P. Orum, Grants

Management Officer, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Room 314, Mail

Stop E–18, Atlanta, Georgia 30305, on or

before August 20, 1996.

1. Deadline: Applications shall be

considered as meeting the deadline if

they are either: a. Received on or before

the deadline date; or b. Sent on or before

the deadline date and received in time

for submission to the objective review

group. (Applicants must request a

legibly dated U.S. Postal Service

postmark or obtain a legibly dated

receipt from a commercial carrier or

U.S. Postal Service. Private metered

postmarks shall not be acceptable as

proof of timely mailing.)

2. Late Applications: Applications

which do not meet the criteria in 1.a. or

1.b. above are considered late

applications. Late applications will not

be considered in the current

competition and will be returned to the

applicant.

Where To Obtain Additional

Information

A complete program description and

information on application procedures

are contained in the application

package. Business management

technical assistance may be obtained

from Locke Thompson, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE, Room 314, Mail

Stop E–18, Atlanta, Georgia 30305,

telephone (404) 842–6593, or through

the Internet or CDC Wonder electronic

mail at: lxt1@opspgo1.em.cdc.gov.

Programmatic technical assistance may

be obtained from Jim Mills, National

Center for Infectious Diseases, Centers

for Disease Control and Prevention

(CDC), 1600 Clifton Road, NE., Mail

Stop G–13, Atlanta, Georgia 30333,

telephone (404) 639–1075, or through

the Internet or CDC Wonder electronic

mail at: jum0@ciddavd1.em.cdc.gov.

Please refer to Announcement

Number 644 when requesting

information regarding this program.

Potential applicants may obtain a

copy of Healthy People 2000 (Full

Report, Stock No. 017–001–00474–0) or

Healthy People 2000 (Summary Report,

Stock No. 017–001–00473–1) referenced

in the Introduction through the

Superintendent of Documents,

Government Printing Office,

Washington, DC 20402–9325, telephone

(202) 512–1800.

Important Notice

Atlanta, Georgia, will be the host of

the 1996 Summer Olympic Games (July

19 through August 4, 1996). As a result

of this event, it is likely that the

Procurement and Grant Office (PGO)

may experience delays in receipt of both

regular and overnight mail deliveries.

Contacting PGO employees during this

time frame may also be hindered due to

possible telephone disruptions.

To the extent authorized, please

consider the use of voice mail, e-mail,

and facsimile transmissions to the

maximum extent practicable. Please do

not fax lengthy documents, contract

proposals or grant applications.

Dated: June 21, 1996.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–16387 Filed 6–26–96; 8:45 am]

BILLING CODE 4163–18–P

[Announcement Number 655]

Emerging Infections Program

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1996

funds for a cooperative agreement

program to establish an Emerging

Infections Program (EIP) to join a

national network of EIPs. This program

will assist in local, State, and national

efforts to conduct surveillance and

applied epidemiologic and laboratory

research in emerging infectious diseases

and to pilot and evaluate prevention

measures. Although only one award will
Federal Register / Vol. 61, No. 125 / Thursday, June 27, 1996 / Notices 33525

be made in FY 1996, CDC may make

additional awards in FY 1997 to

approved applications received and

evaluated under this announcement.

The CDC is committed to achieving

the health promotion and disease

prevention objectives of ‘‘Healthy

People 2000,’’ a national activity to

reduce morbidity and mortality and

improve the quality of life. This

announcement is related to the priority

area of Immunization and Infectious

Diseases. (For ordering a copy of

‘‘Healthy People 2000,’’ see the section

‘‘Where To Obtain Additional

Information.’’)

Authority

This program is authorized under

sections 301(a) [42 U.S.C. 241(a)] and

317(k) [42 U.S.C. 247b(k)] of the Public

Health Service Act, as amended.

Smoke-Free Workplace

CDC strongly encourages all grant

recipients to provide a smoke-free

workplace and to promote the nonuse of

all tobacco products, and Public Law

103–227, the Pro-Children Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day care, health care,

and early childhood development

services are provided to children.

Eligible Applicants

Eligible applicants are the official

public health agencies of States or their

bona fide agents. This includes the

District of Columbia, American Samoa,

the Commonwealth of Puerto Rico, the

Virgin Islands, the Federated States of

Micronesia, Guam, the Northern

Mariana Islands, the Republic of the

Marshall Islands, the Republic of Palau,

and federally recognized Indian tribal

governments. Non-State public health

agency applicants must provide

certification by the State designating the

institution as the State’s official

applicant.

Availability of Funds

Approximately $500,000 is available

in FY 1996 to fund one award. It is

expected that the award will begin on or

about September 30, 1996, and will be

made for a 12-month budget period

within a project period of up to 3 years.

Funding estimates may vary and are

subject to change. Continuation awards

within the project period will be made

on the basis of satisfactory progress and

the availability of funds.

Purpose

The purpose of this cooperative

agreement is to assist State health

departments to establish Emerging

Infections Programs (EIP) as part of a

national network. EIPs will be

population-based centers designed to

assess the public health impact of

emerging infections and to evaluate

methods for their prevention and

control. Activities of the EIPs will fall

into the general categories of: (1) active

surveillance; (2) applied epidemiologic

and applied laboratory research; and (3)

implementation and evaluation of pilot

prevention/intervention projects.

Activities of the EIPs will be focused

in the areas of drug-resistant infections,

foodborne and waterborne diseases, and

vaccine preventable or potentially

vaccine preventable diseases. The EIPs

will maintain sufficient flexibility to

accommodate changes in projects as

required by the emergence of public

health infectious disease problems. EIPs

will be strategically located to serve a

variety of geographical areas, diverse

groups and difficult-to-reach

populations—e.g., underserved women

and children, the homeless, immigrants

and refugees, and persons infected with

HIV. They will enlist the participation

of local health departments, academic

institutions, and other public and

private organizations with an interest in

addressing public health issues relating

to emerging infectious diseases, and will

seek support from sources, in addition

to CDC, to operate the EIP.

Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for the activities

under A. (Recipient Activities), and

CDC will be responsible for the

activities listed under B. (CDC

Activities).

A. Recipient Activities

1. Establish and operate an EIP to

further local, State, and national efforts

to address emerging infectious diseases.

a. Organize the EIP so that it will have

the capacity to conduct approximately

four concurrent projects.

b. Organize the EIP so that it will

maintain the ability to accommodate

changes in specific projects and

priorities as the public health system’s

need for information changes or new

health problems emerge.

c. Operate the EIP so that it can

function effectively as part of a national

network of EIPs. EIPs will need to

coordinate project priorities with CDC

and among themselves to assure that

important emerging infections issues are

addressed appropriately.

d. Establish the EIP in a defined

population, which could include either

an entire State or a geographically

defined area (or areas) within a State. To

accomplish the objectives of certain EIP

activities, a minimum population base

of approximately 1,000,000 may be

necessary.

2. Work to obtain technical and

financial assistance to supplement the

core assistance from CDC, as well as

programmatic collaboration from other

‘‘partner organizations.’’ Partner

organizations may be academic

institutions and other public and private

organizations with an interest in

addressing public health issues relating

to emerging infectious diseases (e.g.,

local public health agencies, public

health laboratories, medical examiners,

university medical schools, schools of

public health, health care providers,

clinical laboratories, community-based

organizations, other Federal and State

government agencies, research

organizations, medical institutions,

foundations, etc.).

3. Propose and conduct emerging

infections activities in collaboration

with appropriate partner organizations.

Collaborate with other EIPs, as

appropriate, to finalize protocols for EIP

activities.

a. Categories of EIP activities.

Activities of the EIP will fall into three

categories:

(1) Active population-based

surveillance projects. These may

include collection and submission of

disease-causing infectious agents to

State, CDC, or other laboratories. For

example, the surveillance case

definition for the condition might

involve detection of a positive culture or

a drug resistant isolate in a microbiology

laboratory, a serologic test result, a

histopathologic finding, or a clinical

syndrome, depending upon the disease

or condition under surveillance; the

specific approach to surveillance could

also vary depending on the disease or

condition under surveillance.

(2) Applied epidemiologic and

applied laboratory projects. Examples of

potential projects include: evaluation of

illnesses often not specifically

diagnosed for which information about

trends and etiology are important (e.g.,

diarrhea, community-acquired

pneumonia); evaluation of drug resistant

infections; evaluation of the clinical

spectrum of influenza and the efficacy

of influenza vaccines in target

populations; investigation of the

relationships between infections and

chronic diseases (e.g., respiratory

infections and asthma attacks);

behavioral surveillance projects

designed to assess trends in behaviors

(e.g., food handling practices, antibiotic

use) that affect the risk for infectious

diseases; assessment of the use and

impact of newer diagnostic tools on the
33526 Federal Register / Vol. 61, No. 125 / Thursday, June 27, 1996 / Notices

diagnosis and management of specific

diseases (e.g., neonatal group B

streptococcal disease, Lyme disease);

evaluation of emerging infectious

diseases in difficult-to-reach

populations, such as persons who do

not have access to routine medical care

or the homeless; examination of

infectious diseases in particular

populations (e.g., studying the

relationship between cervical

papillomavirus infection and cervical

carcinoma in women); evaluation of the

economic impact of infectious diseases

or cost-benefit studies of intervention

strategies.

(3) Implementation and evaluation of

pilot prevention/intervention projects

for emerging infectious diseases.

Examples might include assessment of

efforts to promote safe food preparation

in the home, evaluation of impact of

hand washing promotion on infectious

diseases in child care facilities, or

evaluation of antibiotic prescribing

practices in outpatient settings.

b. Specific EIP activities.

(1) Propose and conduct the following

core activities:

Active population-based laboratory

surveillance for invasive disease caused

by emerging, vaccine preventable, and

drug resistant bacterial diseases, and for

foodborne diseases (for additional

information see Application Content,

Operational Plan, paragraph d. of the

Program Announcement included in the

application kit).

(2) Propose up to 2 additional projects

that could be conducted in the EIP. The

optional projects may be chosen from

the following list (see more complete

description in Application Content,

Operational Plan, paragraph e. of the

Program Announcement included in the

application kit).

(a) Population-based surveillance for

hepatitis,

(b) Surveillance for emerging

etiologies of pneumonia in the U.S.,

(c) Laboratory-based surveillance for

Vancomycin-resistant Gram-positive

pathogens,

(d) Laboratory-based Surveillance for

Clostridium difficile,

(e) Infectious complications

associated with blood transfusion,

(f) Surveillance for emerging

etiologies of protozoal diarrhea,

(g) Surveillance for metronidazoleresistant Trichomonas infection,

(h) Evaluation of prevention of

neonatal group B streptococcal disease,

(i) Active surveillance for Hemolytic

Uremic Syndrome.

4. As a part of certain EIP projects,

provide specimens such as diseasecausing isolates or serum specimens to

appropriate organizations (which may

include CDC) for laboratory evaluation

(e.g., molecular epidemiologic studies,

evaluation of diagnostic tools).

5. Manage, analyze, and interpret data

from EIP projects, and publish and

disseminate important public health

information stemming from EIP projects

in collaboration with CDC.

6. Provide training opportunities (e.g.,

infectious disease fellows).

7. Monitor and evaluate scientific and

operational accomplishments of the EIP

and progress in achieving the purpose

and overall goals of this program.

B. CDC Activities

1. Provide consultation and scientific

and technical assistance in general

operation of the EIP and in designing

and conducting individual EIP projects.

2. Participate in analysis and

interpretation of data from EIP projects.

Participate in the dissemination of

findings and information stemming

from EIP projects.

3. Assist in monitoring and evaluating

scientific and operational

accomplishments of the EIP and

progress in achieving the purpose and

overall goals of this program.

4. As needed, perform laboratory

evaluation of specimens or isolates (e.g.,

molecular epidemiologic studies,

evaluation of diagnostic tools) obtained

in EIP projects and integrate results with

other data from EIP projects.

Notice of Intent To Apply

In order to assist CDC in planning for

and executing the evaluation of

applications submitted under this

announcement, all parties intending to

submit an application are requested to

inform CDC of their intention to do so

at their earliest convenience prior to the

application due date. Notification

should include: (1) name and address of

institution, and (2) name, address, and

telephone number of contact person.

Notification should be provided by

facsimile, postal mail, or E-mail, to Greg

Jones, M.P.A., Funding Resources

Specialist, National Center for Infectious

Diseases (NCID), Centers for Disease

Control and Prevention (CDC), 1600

Clifton Road, NE., Mailstop C–19,

Atlanta, GA 30333, E-mail address

gjj1@cidod1.em.cdc.gov, facsimile (404)

639–4195.

Evaluation Criteria

The applications will be reviewed and

evaluated according to the following

criteria (total 100 points):

1. Understanding the objectives of the

EIP (total 5 points):

The extent to which the applicant

demonstrates a clear understanding of

the objectives of this cooperative

agreement program. The extent to which

the applicant demonstrates a clear

understanding of the requirements,

responsibilities, problems, constraints,

and complexities that may be

encountered in establishing and

operating the EIP.

2. Population Base (total 5 points):

The extent to which the applicant

defines clearly the geographic area and

population base in which the EIP will

operate. The extent to which the

applicant defines a population base for

the EIP that is sufficiently large and

diverse to accomplish proposed EIP

activities. The extent to which the

applicant clearly describes various

special populations in the EIP area, such

as the rural or inner city poor,

underserved women and children, the

homeless, immigrants/refugees, and

persons infected with HIV, that could be

the focus of one or more EIP projects.

3. Capacity (total 35 points):

a. The extent to which the applicant

demonstrates its capacity and ability to

conduct active surveillance, applied

epidemiologic and applied laboratory

research, and prevention research in

emerging infectious diseases (25 points).

b. The extent to which the applicant

demonstrates its ability to develop and

maintain strong cooperative

relationships with various public and

private local and regional medical,

public health, academic, and

community organizations. The extent to

which applicant demonstrates its ability

to solicit and secure financial and

technical support and programmatic

collaboration from other public and

private organizations for conducting

public health research projects. The

extent to which applicant provides

letters of support from non-applicant

participating agencies, institutions,

organizations, individuals, consultants,

etc., indicating their willingness to

participate, as represented in applicant’s

operational plan, in establishing and

operating the center (total 10 points).

4. Operational Plan (total 40 points):

a. The extent to which the applicant’s

proposed plan for establishing and

operating the EIP is detailed and clearly

describes the proposed organizational

and operating structure/procedures and

clearly identifies the roles and

responsibilities of all participating

agencies, organizations, institutions,

and individuals. The extent to which

the applicant describes plans for

collaboration with CDC in the

establishment and ongoing operation of

the EIP and individual EIP projects. The
Federal Register / Vol. 61, No. 125 / Thursday, June 27, 1996 / Notices 33527

extent to which the applicant’s plan

addresses all Recipient Activities listed

in the announcement and appears

feasible and capable of accomplishing

the purpose of the program (15 points).

b. The extent to which the applicant

proposes to conduct the core activities,

as outlined in the Application Content

section of the Program Announcement

included in the application kit. The

extent to which the applicant proposes

potential additional appropriate projects

that could be conducted at the EIP. The

extent to which the proposed core and

additional projects demonstrate that the

applicant understands and is capable of

conducting population-based

surveillance, applied epidemiologic and

applied laboratory studies, and pilot

prevention programs. The quality of the

proposed projects regarding consistency

with public health needs, intent of this

program, feasibility, methodology/

approach, and collaboration/

participation of partner organizations.

The degree to which the applicant has

met the CDC policy requirements

regarding the inclusion of women,

ethnic, and racial groups in proposed

research. This includes: (1) the

proposed plan for the inclusion of both

sexes and racial and ethnic minority

populations for appropriate

representation; (2) the proposed

justification when representation is

limited or absent; (3) a statement as to

whether the design of the study is

adequate to measure differences when

warranted; and (4) documentation of

plans for recruitment and outreach for

study participants that includes the

process of establishing partnerships

with community(ies) and recognition of

mutual benefits (total 15 points).

c. The extent to which the applicant’s

plan clearly describes partnerships with

appropriate organizations for

establishing and operating the proposed

EIP and for conducting individual EIP

projects. Partner organizations may be

academic institutions and other public

and private organizations with an

interest in addressing public health

issues relating to emerging infectious

diseases (e.g., local public health

agencies, public health laboratories,

medical examiners, university medical

schools, schools of public health, health

care providers, clinical laboratories,

community-based organizations, other

Federal and State government agencies,

research organizations, medical

institutions, foundations, etc.). The

extent to which the applicant’s plan

describes possible training

opportunities (e.g., infectious disease

fellows). The extent to which the

applicant proposes a clearly detailed

and viable plan for soliciting and

securing financial and technical

assistance from other public and private

organizations to supplement the core

funding from CDC (total 10 points).

5. Project Management and Staffing

(total 10 points):

The extent to which the applicant

identifies its own professional and

support staff, and professional and

support staff from other agencies,

institutions, and organizations, that

have the experience, authority, and

willingness to carry out recipient

activities as evidenced by job

descriptions, curriculum vitae,

organizational charts, etc. The extent to

which the applicant describes an

approach to maintaining sufficiently

flexible EIP staffing to accommodate the

likelihood that the requirements of EIP

projects will change from time to time.

6. Evaluation (total 5 points):

The extent to which applicant

provides a detailed evaluation plan. The

quality of the proposed plan for

monitoring scientific and operational

accomplishments of the EIP and of

individual EIP projects. The quality of

the proposed evaluation plan for

monitoring progress in achieving the

purpose and overall goals of this

program.

7. Budget (not scored):

The extent to which the proposed

budget is reasonable, clearly justifiable,

and consistent with the intended use of

cooperative agreement funds. The extent

to which both Federal and non-Federal

(e.g., State funding) contributions are

presented.

8. Human Subjects (not scored):

If any proposed project involves

human subjects, whether or not exempt

from the DHHS regulations, the extent

to which adequate procedures are

described for the protection of human

subjects. Note: Objective Review Group

(ORG) recommendations on the

adequacy of protections include: (1)

protections appear adequate and there

are no comments to make or concerns to

raise, or (2) protections appear adequate,

but there are comments regarding the

protocol, or (3) protections appear

inadequate and the ORG has concerns

related to human subjects, or (4)

disapproval of the application is

recommended because the research

risks are sufficiently serious and

protection against the risks are

inadequate as to make the entire

application unacceptable.

Executive Order 12372 Review

Applications are subject to

Intergovernmental Review of Federal

Programs as governed by Executive

Order 12372. E.O. 12372 sets up a

system for State and local government

review of proposed Federal assistance

applications. Applicants (other than

federally recognized Indian tribal

governments) should contact their State

Single Point of Contact (SPOC) as early

as possible to alert them to the

prospective applications and receive

any necessary instructions on the State

process. For proposed projects serving

more than one State, the applicant is

advised to contact the SPOC for each

affected State. A current list of SPOCs

is included in the application kit. Indian

tribes are strongly encouraged to request

tribal government review of the

proposed application. If SPOCs or tribal

governments have any process

recommendations on applications

submitted to CDC, they should forward

them to Sharron P. Orum, Grants

Management Officer, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Mailstop E–18,

Room 314, Atlanta, GA 30305. The due

date for State process recommendations

is 30 days after the application deadline

date for new and competing

continuation awards. The appropriation

for this financial assistance program was

received late in the fiscal year and

would not allow for an application

receipt date which would accommodate

the 60-day State recommendation

process period. CDC does not guarantee

to ‘‘accommodate or explain’’ for State

process recommendations it receives

after that date.

Public Health System Reporting

Requirements

This program is not subject to the

Public Health System Reporting

Requirements.

Catalog of Federal Domestic Assistance

Number

The Catalog of Federal Domestic

Assistance number is 93.283.

Other Requirements

Paperwork Reduction Act

Projects that involve the collection of

information from ten or more

individuals and funded by the

cooperative agreement will be subject to

review by the Office of Management and

Budget (OMB) under the Paperwork

Reduction Act.
33528 Federal Register / Vol. 61, No. 125 / Thursday, June 27, 1996 / Notices

Human Subjects

If the proposed project involves

research on human subjects, the

applicant must comply with the

Department of Health and Human

Services Regulations 45 CFR Part 46,

regarding the protection of human

subjects. Assurance must be provided to

demonstrate that the project will be

subject to initial and continuing review

by the appropriate institutional review

committee. In addition to other

applicable committees, Indian Health

Service (IHS) institutional review

committees also must review the project

if any component of IHS will be

involved or will support the research. If

any American Indian community is

involved, its tribal government must

also approve that portion of the project

applicable to it. The applicant will be

responsible for providing assurance in

accordance with the appropriate

guidelines and form provided in the

application kit.

Women, Racial and Ethnic Minorities

It is the policy of the Centers for

Disease Control and Prevention (CDC)

and the Agency for Toxic Substances

and Disease Registry (ATSDR) to ensure

that individuals of both sexes and the

various racial and ethnic groups will be

included in CDC/ATSDR-supported

research projects involving human

subjects, whenever feasible and

appropriate. Racial and ethnic groups

are those defined in OMB Directive No.

15 and include American Indian,

Alaskan Native, Asian, Pacific Islander,

Black and Hispanic. Applicants shall

ensure that women, racial and ethnic

minority populations are appropriately

represented in applications for research

involving human subjects. Where clear

and compelling rationale exist that

inclusion is inappropriate or not

feasible, this situation must be

explained as part of the application.

This policy does not apply to research

studies when the investigator cannot

control the race, ethnicity and/or sex of

subjects. Further guidance to this policy

is contained in the Federal Register,

Vol. 60, No. 179, pages 47947–47951,

dated Friday, September 15, 1995.

Animal Subjects

If the proposed project involves

research on animal subjects, the

applicant must comply with the ‘‘PHS

Policy on Humane Care and Use of

Laboratory Animals by Awardee

Institutions.’’ An applicant organization

proposing to use vertebrate animals in

PHS-supported activities must file an

Animal Welfare Assurance with the

Office for Protection from Research

Risks at the National Institutes of

Health.

Application Submission and Deadline

The original and two copies of the

application PHS Form 5161–1 (Revised

7/92, OMB Control Number 0937–0189)

must be submitted to Sharron P. Orum,

Grants Management Officer, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Room 314,

Mailstop E–18, Atlanta, GA 30305,

Attention: Marsha Driggans, on or before

August 23, 1996.

1. Deadline: Applications shall be

considered as meeting the deadline if

they are either:

(a) Received on or before the deadline

date; or

(b) Sent on or before the deadline date

and received in time for submission to

the objective review group. (Applicants

must request a legibly dated U.S. Postal

Service postmark or obtain a legibly

dated receipt from a commercial carrier

or U.S. Postal Service. Private metered

postmarks shall not be acceptable as

proof of timely mailing.)

2. Late Applications: Applications

which do not meet the criteria in 1.(a)

or 1.(b) above are considered late

applications. Late applications will not

be considered in the current

competition and will be returned to the

applicant.

Where To Obtain Additional

Information

A complete program description and

information on application procedures

are contained in the application

package. Business management

technical assistance may be obtained

from Marsha Driggans, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Room 314,

Mailstop E–18, Atlanta, GA 30305,

telephone (404) 842–6523, facsimile

(404) 842–6513, E-mail

mdd2@opspgo1.em.cdc.gov or CDC

WONDER.

Programmatic technical assistance

may be obtained from Robert Pinner,

M.D., or Pat McConnon, M.P.H., Office

of the Director, National Center for

Infectious Diseases, Centers for Disease

Control and Prevention (CDC), Mailstop

C–12, 1600 Clifton Road, NE., Atlanta,

GA 30333, telephone (404) 639–2603.

E-mail address for Dr. Pinner:

rwp1@cidod1.em.cdc.gov or CDC

WONDER. E-mail address for Mr.

McConnon: pjm2@cidod1.em.cdc.gov or

CDC WONDER.

Please refer to Announcement

Number 655 when requesting

information and submitting and

application.

Important Notice: Atlanta, GA, will be the

host of the 1996 Summer Olympics Games,

July 19 through August 4, 1996. As a result

of this event, it is likely that the Procurement

and Grants Office (PGO), CDC, may

experience delays in the receipt of both

regular and overnight mail deliveries.

Contacting PGO employees during this time

frame may also be hindered due to the

possible telephone disruptions. To the extent

authorized, please consider the use of voice

mail, E-mail, and facsimile transmission to

the maximum extent practicable. However,

do not fax lengthy documents or grant

applications.

You may obtain this announcement

from one of two Internet sites on the

actual publication date: CDC’s

homepage at http://www.cdc.gov or at

the Government Printing Office

homepage (including free on-line access

to the Federal Register at http://

www.access.gpo.gov).

Potential applicants may obtain a

copy of ‘‘Healthy People 2000’’ (Full

Report, Stock No. 017–001–00474–0) or

‘‘Healthy People 2000’’ (Summary

Report, Stock No. 017–001–00473–1)

referenced in the ‘‘Introduction’’

through the Superintendent of

Documents, Government Printing

Office, Washington, DC 20402–9325,

telephone (202) 512–1800.

Potential applicants may obtain a

copy of ‘‘Addressing Emerging

Infectious Disease Threats: A Prevention

Strategy for the United States’’ through

the Centers for Disease Control and

Prevention (CDC), National Center for

Infectious Diseases, Office of Planning

and Health Communication—EP,

Mailstop C–14, 1600 Clifton Road,

Atlanta, GA 30333. Requests may also

be sent by facsimile to (404) 639–3039.

Dated: June 21, 1996.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–16389 Filed 6–26–96; 8:45 am]

BILLING CODE 4163–18–P

[Announcement Number 664]

Primate Model for Studying the

Pathogenesis of Measles Infections

and for Development of Improved

Measles Vaccines

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1996

funds for a cooperative agreement